OSTEOARTHRITIS: Edited by Mukundan AtturWhat did we learn from ‘omics’ studies in osteoarthritisRuiz-Romero, Cristinaa,b; Rego-Perez, Ignacioc,d; Blanco, Francisco J.a,c,dAuthor Information aRheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC – Hospital Universitario de A Coruña bCIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC cRIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC dRheumatology Division, Genomics Group, INIBIC – Hospital Universitario de A Coruña, 15006 A Coruña, Spain Correspondence to Francisco J. Blanco, MD, PhD, INIBIC-Complejo Hospitalario Universitario A Coruña, C/ Xubias, 84, 15006-A Coruña, Spain. Tel: +34 981 176399; fax: +34 981 176398; e-mail: email@example.com Current Opinion in Rheumatology: January 2018 - Volume 30 - Issue 1 - p 114-120 doi: 10.1097/BOR.0000000000000460 Buy Metrics Abstract Purpose of review ‘Omics’ technologies developed for the massive analysis of the major biologically relevant molecules (genes, proteins, metabolites) have been applied to the study of osteoarthritis (OA) for more than a decade. Recent findings ‘Omics’ studies have undoubtedly contributed to increase the knowledge on pathogenic processes related with OA and have provided hundreds to thousands of molecules that might have a putative biomarker utility for this disease. Summary This review describes the most recent ‘omics’ studies in OA research, their conclusions, and discuss those remaining challenges. Still many validation studies must be performed in large and well-characterized cohorts for the translation of the findings from ‘omics’ strategies to clinical applications. The development of tools for the intelligent integration of ‘omics’ data with clinical and imaging information is also mandatory to take full profit of the work that has been already performed. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.